Logo

OWLT

Owlet, Inc.

OWLT

Owlet, Inc. • NYSE
$13.16 ▼ -0.83% (-0.11)
Market Cap $210.58 M
52w High $13.39
52w Low $2.75
Dividend Yield 0%
P/E -4.68
Volume 81.03K
Outstanding Shares 16.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $31.988M ▲ $14.984M ▼ $4.134M ▲ 12.924% ▲ $0.17 ▲ $5.158M ▲
Q2-2025 $26.063M ▲ $15.276M ▲ $-36.338M ▼ -139.424% ▼ $-2.37 ▼ $-36.513M ▼
Q1-2025 $21.104M ▲ $13.997M ▼ $3.025M ▲ 14.334% ▲ $0.11 ▲ $4.176M ▲
Q4-2024 $20.5M ▼ $18.3M ▲ $-9.052M ▼ -44.156% ▼ $-0.64 ▼ $-7.462M ▼
Q3-2024 $22.122M $16.368M $-5.611M -25.364% $-0.61 $-5.345M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $23.76M ▲ $74.865M ▲ $113.464M ▲ $-38.599M ▲
Q2-2025 $21.827M ▲ $63.543M ▲ $112.4M ▲ $-48.857M ▼
Q1-2025 $16.31M ▼ $51.397M ▲ $63.397M ▼ $-12M ▲
Q4-2024 $20.245M ▼ $49.515M ▼ $70.663M ▼ $-21.148M ▼
Q3-2024 $21.502M $56.13M $73.276M $-17.146M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $4.134M ▲ $-2.17M ▲ $-255K ▼ $4.358M ▼ $1.933M ▼ $-2.425M ▼
Q2-2025 $-37.647M ▼ $-2.245M ▲ $-89K ▲ $7.851M ▲ $5.517M ▲ $-2.334M ▲
Q1-2025 $3.025M ▲ $-5.925M ▼ $-110K ▼ $2.014M ▲ $-4.021M ▼ $-6.035M ▼
Q4-2024 $-9.052M ▼ $3.321M ▲ $-39K ▲ $-4.533M ▼ $-1.251M ▼ $3.282M ▲
Q3-2024 $-5.611M $-7.809M $-648K $14.976M $6.519M $-8.457M

Five-Year Company Overview

Income Statement

Income Statement Owlet’s revenue base is still quite small and has not grown meaningfully over the last few years, though it has held relatively steady rather than collapsing. The company consistently generates positive gross profit, which means the core products are sold above their direct costs. However, overall it remains loss‑making: operating losses and net losses have been the norm every year. The good news is that losses appear to have peaked a couple of years ago and have since narrowed, suggesting cost controls and a more focused business model. Earnings per share have been deeply negative, but the direction of change is improving, not worsening. In plain terms, this is a company that has moved from “heavy bleeding” toward “manageable but still meaningful losses.”

Balance Sheet

Balance Sheet The balance sheet is small and relatively tight. Total assets are limited, with cash making up a large portion of what the company owns. Debt levels are present but not extreme, so the company is not heavily leveraged, but the real concern is equity: book equity has been negative in most years, reflecting accumulated losses that exceed the capital invested. That signals a thin financial cushion and less room to absorb future setbacks without outside support. Overall, the balance sheet points to a company that must manage risk carefully and continue improving its economics to strengthen its financial foundation over time.

Cash Flow

Cash Flow Owlet has been burning cash from its operations for several years, meaning the business has not yet been self‑funding. The worst period of cash burn appears to be behind it, with operating and free cash outflows shrinking more recently, which aligns with the improvement in operating losses. Capital spending has been minimal, so the main drain on cash is running the business rather than big equipment or facility investments. The key takeaway is that while the direction is better, the company still depends on its existing cash and potential external financing to cover ongoing losses until it can reach consistent cash break‑even or better.

Competitive Edge

Competitive Edge Owlet operates in a focused niche within baby and infant monitoring, where safety, reliability, and trust matter more than flashy features. Its main edge comes from offering medical‑grade features—particularly pulse oximetry—rather than just video or motion monitoring. FDA clearances for its core products create a regulatory moat that is difficult and time‑consuming for rivals to replicate, and this supports strong brand recognition among parents and healthcare partners. At the same time, the company faces competition from other premium baby‑monitor brands and from broader consumer‑electronics players. The market is specialized and tied to birth trends and consumer spending on baby tech, so Owlet must keep proving its value and staying ahead on reliability, data quality, and ease of use. Its competitive position is differentiated but not risk‑free, especially given its smaller size versus larger consumer and health‑tech companies.

Innovation and R&D

Innovation and R&D Innovation is a clear strength. Owlet has taken hospital‑grade pulse oximetry and adapted it into a consumer‑friendly wearable, then built an ecosystem around it with cameras, apps, and subscription services. The FDA‑cleared Dream Sock and BabySat highlight the company’s ability to navigate both technology and regulation, while Owlet360 shows a push toward data‑driven insights and recurring software revenue. Partnerships to improve connectivity and integrate with remote‑patient‑monitoring platforms extend the usefulness of its devices beyond the nursery. The proposed prenatal Owlet Band, if revived and successfully launched, would expand the addressable market into pregnancy monitoring, but it also adds execution and regulatory uncertainty. With limited financial resources, Owlet must balance ambitious R&D and product expansion against the need to control costs and prioritize the most commercially promising projects.

Summary

Owlet is a small, innovation‑driven healthcare device company with a strong niche in infant monitoring and a distinctive regulatory edge. Its technology and brand have real strengths, and recent financial trends show better cost control and narrowing losses. However, the business is not yet profitable, the balance sheet is thin with negative equity, and the company continues to consume cash, leaving it dependent on its cash reserves and potential external funding. The long‑term story hinges on whether Owlet can turn its FDA‑backed products, ecosystem, and partnerships into sustainable growth and eventually self‑funded operations, while managing regulatory, competitive, and execution risks along the way.

NEWS

November 19, 2025 · 8:45 AM UTC

Owlet and Locus Health Partner to Seamlessly Deliver Infant Health Data into Remote Patient Monitoring Programs

Read more

November 13, 2025 · 4:16 PM UTC

Owlet Reports Third Quarter 2025 Financial Results

Read more

November 12, 2025 · 8:45 AM UTC

Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs

Read more

October 27, 2025 · 9:00 AM UTC

Kessler Topaz Meltzer & Check, LLP and Pomerantz LLP Announce Proposed Class Action Settlements on Behalf of Owners of Sandbridge Acquisition Corporation Common Stock and/or Purchasers of Owlet, Inc. Common Stock and/or Warrants – SBG SBG.WS SBG.U OWLT OWLTW

Read more

October 22, 2025 · 12:06 AM UTC

Owlet Announces Pricing of Public Offering of Class A Common Stock

Read more